31) AMPLITUDE-O results (2021): That secondary composite renal outcome (UACR >300, UACR ≥30% increase from baseline, ESRD or death from any cause ) favored efpeglenatide 🔓 https://t.co/Jz5inIwWEn https://t.co/vvWfyJLaWw
2,568 followers
96 followers
@DachsClinic 最新のGLP-1RAの比較試験で、SGLT2iがベースラインに入った人が含まれてるものがあります。 SGLT2iを含む含まないに関わらず、同様の傾向であったとのことです(URLの論文のfigure2の下の方です)。 https://t.co/fZ4gEYaM9l
2,262 followers
Gerstein et al. examined the effect of administrating weekly injections of efpeglenatide on cardiovascular and renal outcomes in patients with type 2 diabetes. Read more here: https://t.co/EGiYGMYzBN
1,788 followers
@mikejohansenmd @hagilani While I do still assume this until proven otherwise for now, my preliminary reading of AMPLITUDE-O makes me wonder what the effect size will be (obviously this trial not really setup to answer the question): https://t.co/qm0Hz4WF